Results for tag: "Aliqopa"

The Aliqopa market is a subset of the larger lymphoma drug market, focusing on the development and commercialization of drugs for the treatment of B-cell non-Hodgkin lymphoma (NHL). Aliqopa is a monoclonal antibody that targets the CD20 antigen on B-cells, and is used in combination with chemotherapy to treat NHL. The Aliqopa market is characterized by a high degree of competition, with several companies developing and marketing similar drugs. The market is also characterized by a high degree of innovation, with companies developing new drugs and formulations to improve efficacy and safety. Companies in the Aliqopa market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Genentech, Janssen, Merck, Novartis, and Pfizer. Show Less Read more